Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Nezastomig by Regeneron Pharmaceuticals for Renal Cell Carcinoma: Likelihood of Approval
Nezastomig is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...